Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are Revuforj, a menin inhibitor, which has completed phase 2 clinical trial for the treatment of relapsed or refractory and acute leukemia. The company is revumenib for R/R mNPM1 AML and studying the use of revumenib in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia across the treatment landscape, including in newly diagnosed patients. It also developing  Niktimvo, a colony stimulating factor-1 receptor, blocking antibody, which is in phase 2 clinical trial for the treatment of chronic graft-versus-host disease. The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Syndax Pharmaceuticals, Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on TG Therapeutics (TGTX), Syndax Pharmaceuticals (SN...

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), Syndax Pharmaceuticals (SNDX) and DaVita (DVA)

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Syndax Pharmaceuticals today and set a price target of $29.00. Accordi...

Bank of America Securities Sticks to Its Buy Rating for Syndax Pharmaceuticals (SNDX)

Barclays analyst Etzer Darout assigned a Buy rating to Syndax Pharmaceuticals today and set a price target of $37.00. According to TipRanks, Darout...

Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lineage Therap (LCTX), Syndax Pharmaceuticals (SNDX)...

Analysts’ Top Healthcare Picks: Lineage Therap (LCTX), Syndax Pharmaceuticals (SNDX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Syndax Pharmaceuticals (SNDX) and Rhythm Pharmaceuti...

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Rhythm Pharmaceuticals (RYTM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Syndax Pharmaceuticals (SNDX) and HCA Healthcare (...

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and HCA Healthcare (HCA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on HCA Healthcare (HCA) and Syndax Pharmaceuticals (SNDX). Syndax Ph...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SNDX	$20.58	+0.88%	204.79K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SNDX	$20.58	+0.9%	204.79K
3
4
5
6

SNDX

SNDX

Get Syndax Pharmaceuticals, Inc. Data in Excel

Get Syndax Pharmaceuticals, Inc. Data in Excel